HXHuan Xu

Huan Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Huan Xu has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Jin Ji

    Department of Urology, Changhai Hospital, Shanghai, China

    2 shared publications
  • Zhong Wang

    Department of Urology, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China

    2 shared publications
  • Bin Xu

    Department of Urology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine

    1 shared publication
  • Chong Liu

    Department of Urology, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong, University School of Medicine

    1 shared publication
  • Chong Liu

    Department of Urology, Shanghai Ninth People’s Hospital, Shanghai 200011, China

    1 shared publication
  • Chungen Yao

    Department of Urology, Haining Branch of the First Affiliated Hospital, Zhejiang University, Haining, Zhejiang Province, China

    1 shared publication

Latest Publications

  • Puerarin inhibits Benign prostatic hyperplasia through regulating HIF-1α-HIF-1β/ AKT1/AP-1

    by Meng Gu, Tianye Yang, Qi Chen, Yanbo Chen, Chong Liu, Zhong Wang, Huan Xu, Bin Xu

  • Open Access

    Comparing pretreatment strategies to increase the yield and purity of human urinary extracellular vesicles

    by Chungen Yao, Xi Chen, Yalong Xu, Fubo Wang, Jin Ji, Huan Xu, Jingyi He, Lei Wang, Yun Li


  • Open Access

    Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer

    by Huan Xu, Yanbo Chen, Meng Gu, Chong Liu, Qi Chen, Ming Zhan, Zhong Wang

    Prostate cancer (PCa) is a carcinoma in which fatty acids are abundant. Fatty acid metabolism is rewired during PCa development. Although PCa can be treated with hormone therapy, after prolonged treatment, castration-resistant prostate cancer can develop and can lead to increased mortality. Changes to fatty acid metabolism occur systemically and locally in prostate cancer patients, and understanding these changes may lead to individualized treatments, especially in advanced, castration-resistant prostate cancers. The fatty acid metabolic changes are not merely reflective of oncogenic activity, but in many cases, these represent a critical factor in cancer initiation and development. In this review, we analyzed the literature regarding systemic changes to fatty acid metabolism in PCa patients and how these changes relate to obesity, diet, circulating metabolites, and peri-prostatic adipose tissue. We also analyzed cellular fatty acid metabolism in prostate cancer, including fatty acid uptake, de novo lipogenesis, fatty acid elongation, and oxidation. This review broadens our view of fatty acid switches in PCa and presents potential candidates for PCa treatment and diagnosis.


  • Open Access

    A Novel Urine Exosomal lncRNA Assay to Improve the Detection of Prostate Cancer at Initial Biopsy: A Retrospective Multicenter Diagnostic Feasibility Study

    by Yun Li, Jin Ji, Ji Lyu, Xin Jin, Xing He, Shaojia Mo, Huan Xu, Jingyi He, Zhi Cao, Xi Chen, et al.

    Purpose: This study aimed at developing and validating a novel noninvasive urinary exosome-based post-DRE (digital rectal examination) lncRNA assay to diagnose PCa (prostate cancer) and clinically significant PCa (Gleason score ≥ 7) from the initial prostate biopsy. Methods: A total of 602 urine samples from eligible participants were collected. The expression levels of urinary exosomal PCA3 (prostate cancer antigen 3) and MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) were detected by qPCR (quantitative real-time PCR). Receiver operating characteristic (ROC) analysis was applied to evaluate the diagnostic performance of PCA3, MALAT1 and the lncRNA assay. A decision curve analysis (DCA) and waterfall plots were used to assess the clinical value of the lncRNA assay. Results: Urinary exosomal PCA3 and MALAT1 were overexpressed in PCa and clinically significant PCa (p < 0.001). The lncRNA assay combining PCA3 and MALAT1 had a better diagnostic performance (AUC 0.828) than the current clinical parameters in detecting PCa. More importantly, the lncRNA assay yielded an AUC of 0.831 to detect clinically significant PCa, which is much higher than that of the current clinical parameters. The lncRNA assay was superior to PSA, f/tPSA and the base model for detecting PCa and clinically significant PCa, with a higher net benefit for almost all threshold probabilities. At the cutoff value of 95% sensitivity, the lncRNA assay could avoid 24.2% unnecessary biopsies while only missing 1.2% of the cases of clinically significant PCa. Conclusion: We developed and validated a novel noninvasive post-DRE urine-based lncRNA assay that presented good diagnostic power and clinical utility for the early diagnosis of PCa and high-grade PCa.


  • Open Access

    ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer

    by Huan Xu, Sangsang Li, Yi Sun, Lingfan Xu, Xin Hong, Zhong Wang, Hailiang Hu

    Prostate cancer (PCa) exhibits an elevated level of de novo lipogenesis that provides both energy and basic metabolites for its malignant development. Long-chain polyunsaturated fatty acids (PUFAs) are elongated and desaturated from palmitate but their effects on PCa progression remain largely unknown. Here, we showed that PUFAs were significantly upregulated by androgen deprivation therapy (ADT) and elevated in neuroendocrine (NE)-like PCa cells. The key enzyme of PUFA elongation, ELOVL5, was overexpressed in NE-like PCa cells as well. Furthermore, we demonstrated that knocking down ELOVL5 in enzalutamide resistant NE-like PCa cells diminished the neuroendocrine phenotypes and enzalutamide resistance, while overexpressing ELOVL5 augmented the enzalutamide resistance of PCa cells in vitro and in vivo. Mechanistically, ELOVL5-mediated PUFA elongation enhanced the lipid raft-associated AKT-mTOR signaling activation and therefore contributes to the enzalutamide resistance. These findings suggest that ELOLV5-mediated PUFA elongation may be a potential novel target for the treatment of enzalutamide resistant NE-like PCa.